Medical devices, healthcare technology and the business of care
510(k) clearance · K260545

CONTOUR PLUS BLUE Blood Glucose Monitoring System; CONTOUR NEXT GEN Blood Glucose Monitoring System; CONTOUR NEXT ONE Blood Glucose Monitoring System

Ascensia Diabetes Care · Decision date Aug 27, 2026

FDA DECISIONK260545

What did the FDA decide?

FDA records K260545 as a 510(k) premarket notification, with a decision dated Aug 27, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Aug 27, 2026

FDA source record

Regulatory record facts

Identifier
K260545
Regulatory pathway
510(k) premarket notification
Product code
NBW
Decision code
SESE
Decision date
Aug 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Test, Blood Glucose, Over The Counter.

Product code
NBW
FDA device class
2

FDA decision timeline

  1. K260545 received

    Application receipt date recorded by FDA.

  2. K260545 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NBW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ascensia Diabetes Care

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Valhalla, NY

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records